Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases
BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development. He reports to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.
Dr. Borie joins Cue as the company continues to execute its strategy of identifying and advancing through development those immunology programs with potential to offer clinically meaningful improvements for patients. Cue expects Phase 2 CSU data readout for the CUE-221 program by end of third quarter of 2026. In addition, the company remains on track to initiate a Phase 1 clinical trial of CUE-401, its first-in-class bifunctional IL-2 and TGF-β molecule with potential for broad applications across autoimmune disease, by the end of the fourth quarter. The company recently announced a $50M private placement to further fund clinical development.
"Dr. Borie is an outstanding physician-scientist and clinical development leader whose experience spans discovery, development and advancement of innovative therapies for immune-mediated diseases," said Shao-Lee Lin, M.D., Ph.D., President and Chief Executive Officer of Cue Biopharma. "His deep expertise in immunology and proven leadership across biotechnology and global pharmaceutical organizations will be invaluable as we advance our portfolio of potential new and transformative therapies. I know that Dominic shares our commitment to scientific excellence, collaboration and improving the lives of patients. We are delighted to welcome him to Cue at this exciting stage in the company's evolution."
Dr. Borie brings more than two decades of experience leading research and clinical development organizations in biotechnology and the pharmaceutical industry. Most recently, he served as Strategic Advisor to the CEO and Board of Kyverna Therapeutics, where he previously served as President of Research & Development and founding Chief Executive Officer. Earlier in his career, he held senior leadership positions at Horizon Therapeutics, Genentech, Amgen, and Roche, advancing innovative immunology programs from early development through global clinical studies. Prior to joining industry, he served as Director of the Transplantation Immunology Laboratory at Stanford University and practiced as a transplant surgeon in Paris, France.